 Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Descriptor ID |
D003924
|
| MeSH Number(s) |
C18.452.394.750.149 C19.246.300
|
| Concept/Terms |
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- NIDDM
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
- Diabetes Mellitus, Noninsulin Dependent
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in this website by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 2 | 2 | | 1986 | 1 | 0 | 1 | | 1988 | 6 | 0 | 6 | | 1989 | 4 | 0 | 4 | | 1990 | 4 | 1 | 5 | | 1991 | 3 | 0 | 3 | | 1992 | 11 | 1 | 12 | | 1993 | 6 | 1 | 7 | | 1994 | 10 | 2 | 12 | | 1995 | 21 | 3 | 24 | | 1996 | 22 | 1 | 23 | | 1997 | 18 | 3 | 21 | | 1998 | 5 | 4 | 9 | | 1999 | 5 | 1 | 6 | | 2000 | 25 | 6 | 31 | | 2001 | 11 | 4 | 15 | | 2002 | 18 | 5 | 23 | | 2003 | 7 | 6 | 13 | | 2004 | 21 | 5 | 26 | | 2005 | 27 | 4 | 31 | | 2006 | 28 | 6 | 34 | | 2007 | 20 | 6 | 26 | | 2008 | 28 | 8 | 36 | | 2009 | 19 | 9 | 28 | | 2010 | 25 | 6 | 31 | | 2011 | 31 | 9 | 40 | | 2012 | 26 | 6 | 32 | | 2013 | 34 | 4 | 38 | | 2014 | 42 | 6 | 48 | | 2015 | 30 | 5 | 35 | | 2016 | 39 | 4 | 43 | | 2017 | 25 | 6 | 31 | | 2018 | 40 | 7 | 47 | | 2019 | 33 | 3 | 36 | | 2020 | 14 | 5 | 19 | | 2021 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
Bakris GL, Agarwal R, Filippatos G. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2021 03 18; 384(11):e42.
-
Arosemena M, Meah FA, Mather KJ, Tersey SA, Mirmira RG. Cell-Free DNA Fragments as Biomarkers of Islet ß-Cell Death in Obesity and Type 2 Diabetes. Int J Mol Sci. 2021 Feb 21; 22(4).
-
Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, Venkataraman GR, Wainberg M, Ollila HM, Kiiskinen T, Havulinna AS, Pirruccello JP, Qian J, Shcherbina A. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet. 2021 02; 53(2):185-194.
-
Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 01 07; 42(2):152-161.
-
Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.
-
Zheng NS, Feng Q, Kerchberger VE, Zhao J, Edwards TL, Cox NJ, Stein CM, Roden DM, Denny JC, Wei WQ. PheMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records. J Am Med Inform Assoc. 2020 11 01; 27(11):1675-1687.
-
Oshima M, Neuen BL, Jardine MJ, Bakris G, Edwards R, Levin A, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wada T, Wheeler DC, Perkovic V, Heerspink HJL. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914.
-
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 12 03; 383(23):2219-2229.
-
Prabhakar NR, Peng YJ, Nanduri J. Hypoxia-inducible factors and obstructive sleep apnea. J Clin Invest. 2020 10 01; 130(10):5042-5051.
-
Frazier K, Leone VA. Microbiota Can't Keep Time in Type 2 Diabetes. Cell Host Microbe. 2020 08 12; 28(2):157-159.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|